OncoMatch/Clinical Trials/NCT06600321
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Is NCT06600321 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including ALN-BCAT and Pembrolizumab for advanced hepatocellular carcinoma.
Treatment: ALN-BCAT · Pembrolizumab — The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hepatocellular Carcinoma
Prior therapy
Must have received: systemic therapy — unresectable advanced or metastatic disease
Has had at least one line of systemic therapy for unresectable advanced or metastatic disease
Cannot have received: anti-cancer therapy or investigational drugs
Has received anti-cancer therapy or investigational drugs ≤3 weeks prior to the first dose of study drug
Lab requirements
Liver function
child-pugh class a or b7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Trial Site · Phoenix, Arizona
- Clinical Trial Site · La Jolla, California
- Clinical Trial Site · Los Angeles, California
- Clinical Trial Site · Jacksonville, Florida
- Clinical Trial Site · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06600321 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-cancer therapy or investigational drugs disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages